InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has received a written notice (the ...
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and ...
OpenX Technologies, Inc., one of the world’s leading omnichannel supply-side platforms, today announced the launch of OpenX Attention Targeting, a ...
A patient in China with hepatocellular carcinoma survived 171 days following xenotransplantation with a genetically modified ...
Dr.Thomas L. F. Montgomery Andresen joins from T-Cypher BioFollows breakthrough non-human primate data demonstrating deep ...
-- Dr. Thomas L. F. Montgomery Andresen joins from T-Cypher Bio -- Follows breakthrough non-human primate data demonstrating deep B-cell depletion without cytokine release -- Commit is poised to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results